Zerigo Health is reinventing care delivery for chronic skin conditions by harnessing the proven power of narrowband UVB phototherapy in a portable device that frees your members to treat from anywhere.
Chronic skin conditions like psoriasis, eczema, and vitiligo affect 40 million Americans and represent an increasingly challenging population for payers. Expensive, inconsistent, and largely inaccessible treatment options contribute to significant waste across the healthcare system, resulting in a lose-lose situation for payers and patients.
Today’s most common and effective treatment plans require frequent clinic visits and painful injections, making it an inconvenient and unsustainable option for many.
Advanced pharmacological treatments cost health plans $35-95k+ per member per year1, and often carry side-effects that can incur further costs.
While advanced therapies are an effective treatment for certain patients, they can negatively impact member outcomes when prescribed indiscriminately.
The Zerigo Skin Health Platform is a broadly effective, holistic solution that can be used as a standalone treatment or combined with advanced therapies to reduce dose escalation.
See How it WorksZerigo’s advanced engagement engine helps us deliver the best possible member results by identifying, targeting, and engaging your best-fit members. This tailored approach is a key way we help our health plan partners drive better outcomes, maximum cost savings, and eliminate waste.
The Zerigo Skin Health Platform is the first to offer clinical grade, FDA-cleared UVB phototherapy treatment in a handheld device. We combine our portable device with a mobile app that guides members through their personalized treatment plan, while tracking results and keeping them connected to licensed providers.
Zerigo’s tailored programs ensure providers have the tools to deliver the highest standard of care for all your members. We partner with CirrusMD to offer virtual visits with licensed providers who diagnose conditions and prescribe treatment. Then, we pair members with a licensed Care Guide who monitors progress and supports members throughout their journey.
The Zerigo Skin Health Platform was built by healthcare experts to fit seamlessly into your current techstack, with services that make implementation, reporting, and analysis a breeze.
Industry average adherence is only 40% among oral medication and 62% among biologic users.
Per member per year, with 53% of patients able to decrease or stop other medications while on the Zerigo platform.
Short implementation timelines and on-demand customer support help you realize ROI faster.
The Zerigo Skin Health Platform adapts to meet your complex needs and the needs of your members—eliminating waste and boosting member satisfaction.
Our holistic solution combines hardware, software and human-led care to achieve excellent adherence and clinical-grade results. Members receive complete support throughout their treatment journey through a mobile app, remote monitoring and expert coaching, without the hassle of in-office treatments.
Zerigo’s treatment platform helps health plans cut waste and realize significant cost savings with a highly effective alternative to expensive and inconsistent advanced therapies. Phototherapy is a broadly effective treatment that calms overactive immune cells, decreases inflammation and promotes normal skin barrier growth without suppressing the immune system.
Working with Zerigo is easy by design. We understand the complexities of the healthcare technology landscape and reflect that in our commitment to adaptability. Our platform easily integrates with your existing workflows and can be implemented in 30 days. We fit seamlessly into your system, so you can focus on caring for your members.
Let’s discuss how partnering with Zerigo can help you support your members and meet your business goals.
1 Based on third party actuarial data on chronic skin condition advanced therapy costs among 30 million commercial plan members 2 Springer Dermatological Research; Adjunctive Treatment of Atopic Dermatitis with Novel At-Home Handheld Narrow-Band UVB Phototherapy 3 Journal of Drugs in Dermatology; The Impact of At-Home Narrow-Band UVB Phototherapy for Mild-to-Severe Psoriasis 4 One year pilot with large national PBM conducted with commercial health plan members